1127: Top 5 Most Read RNS's on Vox Markets for Tuesday 17th January 2023

The Vox Markets Podcast

Top 5 Most Read RNS's on Vox Markets for Tuesday 17th January 2023
5. Union Jack Oil #UJO - Operational Update

Wressle-PEDL180/182 (Union Jack 40%) - Cumulative oil production of more than 341,100 barrels to 12 January 2023, with zero water-cut.
Current daily production rate of approximately 825-850 barrels of oil per day ("bopd"), however, a daily rate of in excess of 1,000 bopd was achieved during December 2022, following a maintenance shut-down of four days
4. THG PLC #THG - Trading statement for the period ended 31 Dec 2022

Record sales of £2.25 billion in FY 2022, with +9.4% growth in THG Beauty and THG Nutrition primary territories1.
Free cash generation2 of c. £50 million in H2 2022, driving strong balance sheet and liquidity with c. £640 million of cash and available facilities at year end.
3. hVIVO PLC #HVO - EUR3.2m Venn contract with global pharma client

hVIVO plc announces its consultancy services division, Venn Life Sciences, has signed a contract with a major global pharmaceutical client worth €3.2m over two years.
2. Nanosynth Group #NNN - Corporate and Commercial Update

2022 was a year of substantial progress for the Group in which we have successfully transitioned from acquiring a university spin-out to a business with some excellent, viable commercial opportunities in fast-growing markets.
The Board is now firmly of the view that the Group has clear direction and a detailed execution plan.
1. Avacta Group #AVCT - Successful Completion of Fourth Dose Escalation

Avacta announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumour biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumour tissue confirming the tumour targeting potential of the pre|CISIONTM technology.